Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Genmab ( ($GMAB) ) just unveiled an update. On August 13, 2025, Genmab A/S announced updates to its Articles of Association, including ...

Genmab (Otc) (($GMAB)) has held its Q2 earnings call. Read on for the main highlights of the call. Genmab’s recent earnings call reflects a ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in follicular lymphoma (FL). | Genmab and AbbVie have presented new data that could ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in ...

Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key ...

Copenhagen, Denmark Saturday, August 9, 2025, 13:00 Hrs [IST] ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Genmab shares were 6% higher, at $22.72 a share, after the company reported positive results of a Phase 3 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide in ...

Genmab A/S today announced changes to its Executive Committee to support Genmab’ s growth and evolution into a fully integrated biotech innovation powerhouse. Genmab’ s Executive Committee ...